Therapeutic gene modified cell based cancer vaccines

Gene

Volumn 525, Issue 2, 2013, Pages 200-207

  Kozłowska, Anna ^a   Mackiewicz, Jacek ^a,b   Mackiewicz, Andrzej ^a,b,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b GREATER POLAND CANCER CENTER   (Poland)

^c Biocontract Spz oo Poznań ^*  (Poland)

Author keywords

Genetically modified tumor vaccines; Immunotherapy; Therapeutic cancer vaccines

Indexed keywords

ADENOVIRUS VECTOR; AGI 101H; BCG VACCINE; BELAGENPUMATUCEL L; CANCER STEM CELL BASED VACCINE; CANCER VACCINE; CELL BASED TUMOR VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B7 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; MELACINE; MELAN A; MELANOMA ANTIGEN 3; MVAX DINITROPHENYL; ONAMELATUCEL L; PLASMID DNA; RENIALE; RETROVIRUS VECTOR; SIPULEUCEL T; TALIMOGENE LAHERPAREPVEC; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VACCINIA ONCOLYSATE; VELIMOGENE ALIPLASMID;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STEM CELL; DNA MODIFICATION; DRUG DESIGN; DRUG MECHANISM; FEVER; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; MELANOMA METASTASIS; MYALGIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SURVIVAL RATE; SWELLING; VIRAL GENE DELIVERY SYSTEM;

(CD80) CLUSTER OF DIFFERENTIATION 80; AAV; ABCB5+; ACUTE MYELOID LEUKEMIA; AD6; ADENO-ASSOCIATED VIRUSES; ADENOVIRUS SEROTYPE 6; ALDEHYDE DEHYDROGENASE; ALDH; AML; ANTIGEN PRESENTING CELLS; APCS; ATP-BINDING CASSETTE SUB-FAMILY B MEMBER 5; B7.1; BACILLUS CALMETTE-GUÉRIN VACCINE; BCG; CANCER STEM CELLS; CDNA; CMV; COMPLEMENTARY DNA; CSCS; CTLA-4; CYTOMEGALOVIRUS; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DCS; DENDRITIC CELLS; DEOXYRIBONUCLEIC ACID; DNA; EGT; ELECTRO-GEN-TRANSFER; GENETICALLY MODIFIED TUMOR VACCINE; GENETICALLY MODIFIED TUMOR VACCINES; GLYCOPROTEIN 100; GLYCOPROTEIN 130; GM-CSF; GMTV; GP100; GP130; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; H6; HER2/NEU; HIV-1; HLA; HPV; HTERT; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN LEUKOCYTE ANTIGEN; HUMAN PAPILLOMAVIRUS; HUMAN SIMIAN IMMUNODEFICIENCY VIRUS; HUMAN TELOMERASE; HYPER INTERLEUKIN 6; ICAM-1; IDO; IFNΆ; IFNΓ; IL-10; IL-12; IL-15; IL-2; IL-4; IL-6; IL-7; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3-DIOXYGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON ALPHA; INTERFERON GAMMA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; JAK; JANUS KINASE; LFA-3; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 3; MAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAPK; MART-1; MDSCS; MELANOMA ANTIGEN RECOGNIZED BY T-CELLS 1; MELANOMA STEM CELLS; MELANOMA-ASSOCIATED ANTIGEN; MHC; MITOGEN-ACTIVATED PROTEIN KINASE; MOLONEY MURINE LEUKEMIA VIRUS; MOMLV; MSCS; MYELOID-DERIVED SUPPRESSOR CELLS; NATURAL KILLER CELLS; NK CELLS; OS; OVERALL SURVIVAL; PD-1; PHOSPHATIDYLINOSITIDE 3-KINASE; PI3K; PROGRAMMED CELL DEATH PROTEIN 1; RECIST; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RIBONUCLEIC ACID; RNA; SHORT INTERFERING RNA; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; SIRNA; SIV; SSEA-1; STAGE-SPECIFIC EMBRYONIC ANTIGEN 1; STAT; T REGULATORY CELLS; T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 3; T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 4; T-REGS; TAAS; TAMS; TGFΒ; THERAPEUTIC CANCER VACCINES; TIM-3; TIM-4; TRANSFORMING GROWTH FACTOR BETA; TUMOR ASSOCIATED ANTIGENS; TUMOR-ASSOCIATED MACROPHAGES; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

CANCER VACCINES; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASTIC STEM CELLS; TISSUE EXTRACTS; TUMOR MICROENVIRONMENT; VACCINES, DNA;

EID: 84879880747     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.056     Document Type: Article

References (67)

1. Abdullah L.N., Chow E.K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2013, 2(1):3. (Jan 17).
2. Alfaro C., et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J. Immunol. 2011, 187:6130-6142.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
4. Apetoh L., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
5. Aurisicchio L., Ciliberto G. Genetic cancer vaccines: current status and perspectives. Expert. Opin. Biol. Ther. 2012, 8:1043-1058.
6. Baghdadi M., et al. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol. Immunother. 2013, 62(4):629-637.
7. Basak G.W., Zapala L., Wysocki P.J., Mackiewicz A., Jakóbisiak M., Lasek W. Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. Oncol. Rep. 2008, 5:1173-1179.
8. Baum C.M., Weissman I.L., Tsukamoto A.S., Buckle A.M., Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(7):2804-2808. (Apr 1).
9. Bedikian A.Y., Richards J., Kharkevitch D., Atkins M.B., Whitman E., Gonzalez R. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010, 3:218-226.
10. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol. Cancer 2011, 10:128.
11. Berd D., Maguire H.C., McCue P., Mastrangelo M.J. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol. 1990, 11:1858-1867.
12. Bilusic M., Gulley J.L. Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol. Immunother. 2012, 1:109-117.
13. Block M.S., et al. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res. 2011, 5:438-445.
14. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3(7):730-737. (Jul).
15. Bose D., et al. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br. J. Cancer 2011, 105:1759-1767.
16. Chan K.S., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14016-14021.
17. Chouaib S., Messai Y., Couve S., Escudier B., Hasmim M., Noman M.Z. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol. 2012, 3:21.
18. Chowdhery R., Gonzalez R. Immunologic therapy targeting metastatic melanoma: allovectin-7. Immunotherapy 2011, 1:17-21.
19. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17:313-319.
20. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 1893, 105:487-511.
21. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
22. Dalerba P., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:10158-10163.
23. Dharmapuri S., et al. Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates. Mol. Ther. 2009, 10:1804-1813.
24. Eggermont M.M. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin. Cancer Res. 2009, 15:6745-6747.
25. Fang D., et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005, 65:9328-9337.
26. Goel S., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91(3):1071-1121. (Jul).
27. Hanna M.G. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Hum. Vaccin. Immunother. 2012, 8(8). (Aug 1, [Epub ahead of print]).
28. Hermann P.C., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
29. Higano C.S., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115(16):3670-3679.
30. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res. 1984, 44:5156-5160.
31. Hoos A., et al. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010, 102:1388-1397.
32. Hsueh E.C., Morton D.L. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin. Cancer Biol. 2003, 13(6):401-407.
33. Kantoff P.W., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363:411-422.
34. Kortylewski M., Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr. Opin. Immunol. 2008, 2:228-233.
35. Low L., et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum. Gene Ther. 2009, 11:1269-1278.
36. Mackiewicz A. Vaccine compositions. EP 2 252 322 (2009), Mackiewicz A, Wysocki PJ, Suchorska W. Vaccine compositions. US2011002898 (2010).
37. Mackiewicz J. What is new in the treatment of advanced melanoma? State of the art. Contemp. Oncol. 2012, 16:363-370.
38. Mackiewicz J., Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur. J. Pharmacol. 2009, 625:84-89.
39. Mackiewicz A., et al. Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum. Gene Ther. 1995, 6:805-811.
40. Mackiewicz A., et al. Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin. Investig. Drugs 2012, 21:773-783.
41. Nauts H.C., McLaren J.R. Coley toxins - the first century. Adv. Exp. Med. Biol. 1990, 267:483-500.
42. Ning N., et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012, 72:1853-1864.
43. Ozbek S., et al. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene 2001, 20:972-979.
44. Pellegrini M., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009, 15:528-536.
45. Prince M.E., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:973-978.
46. Rizzuto G., et al. Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure. Hum. Gene Ther. 2000, 11:1891-1900.
47. Rose-John S., Waetzig G.H., Scheller J., Grötzinger J., Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets 2007, 5:613-624.
48. Schatton T., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
49. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
50. Schwartzentruber D.J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364:2119-2127.
51. Singh S.K., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
52. Small E.J., et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 2007, 13:3883-3891.
53. Steg A.D., et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 2012, 18:869-881.
54. Szybalska E.H., Szybalski W. Genetics of human cell lines. IV. DNA mediated heritable transformation of a biochemical trait. Proc. Natl. Acad. Sci. 1962, 48:2026-2034.
55. Szybalski W. Roots: use of the HPRT gene and the HAT selection technique in DNA-mediated transformation of mammalian cells: first steps toward developing hybridoma techniques and gene therapy. BioEssays 1992, 14:495-500.
56. Vaishampayan U., Abrams J., Darrah D., Jones V., Mitchell M.S. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin. Cancer Res. 2002, 12:3696-3701.
57. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271.
58. Visvader J.E., Lindeman G.J. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012, 10:717-728.
59. Waldron N.N., et al. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol. Cancer Ther. 2011, 10(10):1829-1838. (Oct).
60. Ward J.E., McNeel D.G. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert. Opin. Biol. Ther. 2007, 7:1893-1902.
61. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 2011, 11(6):393-410. (Jun).
62. Wiznerowicz M., Fong A.Z., Mackiewicz A., Hawley R.G. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development. Gene Ther. 1997, 10:1061-1068.
63. Wysocki P.J., Kazimierczak U., Suchorska W., Kotlarski M., Malicki J., Mackiewicz A. Gene-modified tumor vaccine secreting a designer cytokine hyper-interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther. 2010, 7:465-475.
64. Xu Q., et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009, 8:1734-1740.
65. Yaddanapudi K., et al. Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible?. PLoS One 2012, 7:e42289.
66. Yang Z.F., et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
67. Zhang Z., Chen X., Chang X., Ye X., Li Y., Cui H. Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer. Int. J. Mol. Med. 2012, (Nov 22). 10.3892/ijmm.2012.1195.